Julian Adams, President and Chief Science Officer ofClal Biotechnology Industries Ltd. (TASE:CBI) said,"We'll do as much outsourcing as possible. That's not happening just at Clal Biotechnology; I'd also do it at a US company. I see no logic in a high overhead in addition to the expensive clinical trials. We'll look for investments everywhere, but we'll concentrate on Boston, because I have a lot of connections there, and on Israel, because here Clal Biotechnology has a lot of connections."